newwin
Luciann Nguyen
Settings
← Accounts
pharma · Rahway, US

Merck & Co.

63
Account opportunity
Not established
Relationship
2
Active signals
2
Trials as sponsor

Why this account matters

Merck & Co.

New trial — A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

New trialNCT06345729
63/100
Opportunity
Commercial fit12/25
Clinical timing18/20
Biomarker need10/20
Relationship2/10
Signal strength9/10
Account value7/10
Urgency5/5

New phase 3 trial NCT06345729 posted by Merck Sharp & Dohme LLC: "A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)". New trial on a phase 3 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated today.

ConfidenceHigh · 95%clinical development · translational medicine · clinical operations
Draft outreachReview

NextMap clinical development and translational medicine stakeholders on the sponsor, confirm no colleague is mid-conversation, then draft evidence-based outreach.

Merck & Co.

New trial — Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

New trialNCT03486873
44/100
Opportunity
Commercial fit5/25
Clinical timing18/20
Biomarker need0/20
Relationship2/10
Signal strength9/10
Account value7/10
Urgency3/5

New phase 3 trial NCT03486873 posted by Merck Sharp & Dohme LLC: "Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)". New trial on a phase 3 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 5 days ago.

ConfidenceHigh · 80%clinical development · translational medicine · clinical operations
Draft outreachReview

NextHold. Score is below the tenant threshold (55). Keep on the watchlist for follow-on signals.

Trials

TrialPhaseTesting language
NCT06345729
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
phase 3
mol. elig.
NCT03486873
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
phase 3
—